Modulation of an individual's gut microbiome to address osteoporosis and bone disease
Tye Jensen, Telluride, CO (US); and Joseph E. Kovarik, Englewood, CO (US)
Assigned to Seed Health, Inc., Venice, CA (US)
Filed by Seed Health, Inc., Venice, CA (US)
Filed on May 4, 2023, as Appl. No. 18/143,399.
Application 18/143,399 is a continuation in part of application No. 17/893,384, filed on Aug. 23, 2022.
Application 17/893,384 is a continuation in part of application No. 17/694,775, filed on Mar. 15, 2022.
Application 17/694,775 is a continuation in part of application No. 17/023,736, filed on Sep. 17, 2020, granted, now 11,419,903, issued on Aug. 23, 2022.
Application 17/023,736 is a continuation in part of application No. 17/011,175, filed on Sep. 3, 2020, granted, now 11,273,187, issued on Mar. 15, 2022.
Application 17/011,175 is a continuation in part of application No. 16/722,117, filed on Dec. 20, 2019, granted, now 10,842,834.
Application 16/722,117 is a continuation in part of application No. 16/229,252, filed on Dec. 21, 2018, granted, now 10,512,661.
Application 16/229,252 is a continuation in part of application No. 15/392,173, filed on Dec. 28, 2016, granted, now 10,245,288.
Application 15/392,173 is a continuation in part of application No. 16/917,096, filed on Jun. 30, 2020, granted, now 10,940,169.
Application 16/917,096 is a continuation in part of application No. 16/782,364, filed on Feb. 5, 2020, granted, now 10,835,560.
Application 16/782,364 is a continuation in part of application No. 16/423,375, filed on May 28, 2019, granted, now 10,555,976.
Application 16/423,375 is a continuation of application No. 16/160,336, filed on Oct. 15, 2018, granted, now 10,314,866.
Application 16/160,336 is a continuation of application No. 15/403,823, filed on Jan. 11, 2017, granted, now 10,111,913.
Application 15/403,823 is a continuation in part of application No. 15/270,034, filed on Sep. 20, 2016, granted, now 9,750,802.
Application 15/270,034 is a continuation in part of application No. 14/954,074, filed on Nov. 30, 2015, granted, now 9,457,077.
Application 14/954,074 is a continuation in part of application No. 16/426,346, filed on May 30, 2019, granted, now 10,716,815.
Application 16/426,346 is a continuation of application No. 15/639,767, filed on Jun. 30, 2017, granted, now 10,314,865.
Application 15/639,767 is a continuation in part of application No. 15/437,976, filed on Feb. 21, 2017, granted, now 9,730,967.
Application 15/437,976 is a continuation in part of application No. 15/228,454, filed on Aug. 4, 2016, granted, now 9,585,920.
Application 15/228,454 is a continuation in part of application No. 14/954,074, filed on Nov. 30, 2015, granted, now 9,457,077.
Application 14/954,074 is a continuation in part of application No. 16/776,861, filed on Jan. 30, 2020, granted, now 10,864,109.
Application 16/776,861 is a continuation of application No. 16/142,171, filed on Sep. 26, 2018, granted, now 10,548,761.
Application 16/142,171 is a continuation in part of application No. 15/395,419, filed on Dec. 30, 2016, granted, now 10,086,018.
Application 15/395,419 is a continuation in part of application No. 16/904,056, filed on Jun. 17, 2020, granted, now 11,523,934.
Application 16/904,056 is a continuation in part of application No. 15/983,250, filed on May 18, 2018, granted, now 10,687,975.
Application 15/983,250 is a continuation in part of application No. 15/384,716, filed on Dec. 20, 2016, granted, now 9,987,224.
Claims priority of provisional application 62/275,341, filed on Jan. 6, 2016.
Claims priority of provisional application 62/296,186, filed on Feb. 17, 2016.
Claims priority of provisional application 62/274,550, filed on Jan. 4, 2016.
Claims priority of provisional application 62/387,405, filed on Dec. 24, 2015.
Prior Publication US 2023/0285473 A1, Sep. 14, 2023
1. A method for reducing the likelihood of developing osteoporosis in an individual human being, comprising: providing via oral administration a population of beneficial bacteria that produce butyrate, said beneficial bacteria encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid, said beneficial bacterial comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzi and Akkermansia muciniphila; and administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual human being.